Unnamed: 0,title,date,stock,sentiment
1254992.0,TrovaGene Q1 EPS $(0.410) Up From $(1.020) YoY,2020-05-07 17:02:00-04:00,TROV,neutral
1254993.0,"Trovagene Reports Corporate Name Change To Cardiff Oncology, Will Trade Under Ticker 'CRDF'",2020-05-06 08:16:00-04:00,TROV,neutral
1254994.0,16 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-04-29 07:35:00-04:00,TROV,neutral
1254995.0,"Trovagene Reports Ongoing Phase 1b/2 Trial For Onvansertib In Combo With FOLFIRI, Avastin Enrolled 12 Patients With 88% Response In 7 Of 8 Evaluable Patients, To-Date 3 Patients With Partial Response, 4 Patients With Stable Disease",2020-04-28 08:18:00-04:00,TROV,positive
1254996.0,Trovagene Granted $305K Loan Pursuant To Paycheck Protection Program,2020-04-17 16:05:00-04:00,TROV,positive
1254997.0,"The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company",2020-03-20 07:44:00-04:00,TROV,negative
1254998.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-19 10:49:00-04:00,TROV,negative
1254999.0,"The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection",2020-03-19 07:37:00-04:00,TROV,neutral
1255000.0,Stocks That Hit 52-Week Lows On Wednesday,2020-03-18 11:37:00-04:00,TROV,negative
1255001.0,"The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates",2020-03-18 07:36:00-04:00,TROV,positive
1255002.0,"The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment",2020-03-17 08:48:00-04:00,TROV,neutral
1255003.0,"TrovaGene Q4 EPS $(0.51) Up From $(1.09) YoY, Sales $93K Up From $78K YoY",2020-02-27 16:40:00-05:00,TROV,neutral
1255004.0,77 Biggest Movers From Yesterday,2020-02-14 04:59:00-05:00,TROV,neutral
1255005.0,58 Stocks Moving In Thursday's Mid-Day Session,2020-02-13 12:22:00-05:00,TROV,neutral
1255006.0,"The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO",2020-02-13 08:05:00-05:00,TROV,negative
1255007.0,Trovagene Reports Presentation Of Phase 2 Data Showing Ability Of Onvansertib To Overcome Zytiga Resistance,2020-02-13 08:02:00-05:00,TROV,positive
1255008.0,The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight,2020-02-09 15:22:00-05:00,TROV,neutral
1255009.0,Trovagene Reports Receives ~$1.45M From Exercise Of Warrants,2020-01-29 08:08:00-05:00,TROV,neutral
1255010.0,Noble Capital Reinstates Outperform on TrovaGene,2020-01-28 10:46:00-05:00,TROV,positive
1255011.0,Trovagene Says Onvasertib Demonstrated Effectiveness As Pan-KRAS Inhibitor With Confirmed Tumor Regression And Clinical Benefit Achieved In KRAS-Mutated mCRC Patients,2020-01-27 08:03:00-05:00,TROV,neutral
1255012.0,98 Biotechnology Stocks Moving In Wednesday's Session,2020-01-22 13:33:00-05:00,TROV,neutral
1255013.0,Trovagene To Present New Clinical Data For Onvansertib In Metastatic KRAS-Mutated Colorectal Cancer At ASCO 2020 Gastrointestinal Cancers Symposium,2020-01-21 08:03:00-05:00,TROV,negative
1255014.0,Trovagene Announces Data Showing 'Ability of Onvansertib to Rescue Venetoclax-Resistance in Acute Myeloid Leukemia',2019-12-04 08:04:00-05:00,TROV,positive
1255015.0,"The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More",2019-12-01 09:30:00-05:00,TROV,neutral
1255016.0,30 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-11-15 08:14:00-05:00,TROV,neutral
1255017.0,48 Stocks Moving In Thursday's Mid-Day Session,2019-11-14 12:18:00-05:00,TROV,neutral
1255018.0,"Benzinga Pro's Top 5 Stocks To Watch For Thurs., Nov. 14, 2019: NVDA, SINA, DDS, TROV, AMRN",2019-11-14 08:44:00-05:00,TROV,positive
1255019.0,"Trovagene Reports Data In Metastatic Prostate Cancer Phase 2 Trial: 72% Of Patients Had Decreases In PSA Levels, 60% Completed 3-Month Treatment",2019-11-14 08:04:00-05:00,TROV,negative
1255020.0,"TrovaGene Q3 EPS $(0.71) Down From $(0.18) YoY, Sales $52K Down From $88K YoY",2019-11-07 17:03:00-05:00,TROV,neutral
1255021.0,TrovaGene shares are trading higher despite no company-specific news. This could potentially be a rebound after the stock dropped approximately 24% over the past 3 trading sessions.,2019-10-30 10:10:00-04:00,TROV,positive
1255022.0,46 Biggest Movers From Yesterday,2019-10-29 05:39:00-04:00,TROV,neutral
1255023.0,40 Stocks Moving In Monday's Mid-Day Session,2019-10-28 12:55:00-04:00,TROV,neutral
1255024.0,TrovaGene shares are trading lower on continued momentum after the company announced a $5 million private placement at $11.814 per share.,2019-10-28 11:32:00-04:00,TROV,positive
1255025.0,Trovagene Announces $5M Private Placement at $1.814/Share,2019-10-25 13:38:00-04:00,TROV,neutral
1255026.0,TrovaGene shares are trading higher despite no company specific news. The stock has rallied approximately 147% over the past 4 days as it continues to trade on higher-than-average volume.,2019-10-25 10:03:00-04:00,TROV,positive
1255027.0,TrovaGene shares are trading higher despite no company-specific news. The stock is trading on higher-than-average volume.,2019-10-24 11:55:00-04:00,TROV,positive
1255028.0,TrovaGene shares are trading lower despite no company-specific news. The stock is trading on higher-than-average volume.,2019-10-23 15:15:00-04:00,TROV,positive
1255029.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Wednesday, October 23, 2019",2019-10-23 09:53:00-04:00,TROV,positive
1255030.0,33 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-10-23 08:48:00-04:00,TROV,neutral
1255031.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Tuesday, October 22, 2019",2019-10-22 10:20:00-04:00,TROV,positive
1255032.0,"Trovagene Highlights Response To Treatment In Patients Enrolled In Phase 1b/2 Trial Of Onvansertib In Combo With FOLFIRI, Avastin: Decreases In Tumor KRAS Mutational Burden In Response To Treatment Was Observed In All 4 Patients Who Completed First Cycle",2019-10-22 08:19:00-04:00,TROV,negative
1255033.0,Stocks That Hit 52-Week Lows On Friday,2019-10-11 10:22:00-04:00,TROV,negative
1255034.0,"The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO",2019-10-10 07:31:00-04:00,TROV,neutral
1255035.0,Stocks That Hit 52-Week Lows On Wednesday,2019-10-09 12:55:00-04:00,TROV,negative
1255036.0,"The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug",2019-10-09 07:58:00-04:00,TROV,negative
1255037.0,25 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-10-02 08:54:00-04:00,TROV,neutral
1255038.0,"The Daily Biotech Pulse: J&J Settles Ohio Opioid Lawsuit, Teligent Explores Options For Certain Assets, Novartis Reports Cosentyx Data",2019-10-02 07:17:00-04:00,TROV,positive
1255039.0,Stocks That Hit 52-Week Lows On Tuesday,2019-10-01 14:35:00-04:00,TROV,negative
1255040.0,"A Look At Benzinga Pro's Most-Searched Tickers For October 1, 2019",2019-10-01 12:58:00-04:00,TROV,neutral
1255041.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Tuesday, October 01, 2019",2019-10-01 09:32:00-04:00,TROV,positive
1255042.0,Trovagene Presents Overview Of Phase 1b/2 Trial Of Onvansertib In Patients With KRAS-Mutated Metastatic Colorectal Cancer (mCRC) At ESMO,2019-10-01 08:17:00-04:00,TROV,negative
1255043.0,"A Look At Benzinga Pro's Most-Searched Tickers For September 30, 2019",2019-09-30 12:05:00-04:00,TROV,neutral
1255044.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Monday, September 30, 2019",2019-09-30 11:31:00-04:00,TROV,positive
1255045.0,18 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-09-30 08:44:00-04:00,TROV,neutral
1255046.0,Trovagene Highlights Presentation Of Phase 1b/2 Study Of Onvansertib At Society For Medical Oncology Conference,2019-09-30 08:17:00-04:00,TROV,neutral
1255047.0,"The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave",2019-09-27 07:56:00-04:00,TROV,positive
1255048.0,The Week Ahead In Biotech: Spotlight On ESMO Conference,2019-09-22 16:22:00-04:00,TROV,neutral
1255049.0,rovagene Announces Completion Of Phase 1b Trial Of Onvansertib In Acute Myeloid Leukemia And Initiation Of Patient Enrollment In Phase 2,2019-09-19 08:16:00-04:00,TROV,neutral
1255050.0,50 Stocks Moving In Thursday's Mid-Day Session,2019-09-12 13:39:00-04:00,TROV,neutral
1255051.0,33 Stocks Moving in Thursday's Pre-Market Session,2019-09-12 07:59:00-04:00,TROV,neutral
1255052.0,50 Biggest Movers From Yesterday,2019-08-27 05:20:00-04:00,TROV,neutral
1255053.0,30 Stocks Moving In Monday's Mid-Day Session,2019-08-26 12:40:00-04:00,TROV,neutral
1255054.0,"A Look At Benzinga Pro's Most-Searched Tickers For August 26, 2019",2019-08-26 11:49:00-04:00,TROV,neutral
1255055.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Monday., August 26, 2019",2019-08-26 09:26:00-04:00,TROV,positive
1255056.0,Trovagene Highlights Presentation Of Clinical Data From Ongoing Phase 2 Study Of Onvansertib In Metastatic Castration-Resistant Prostate Cancer,2019-08-26 08:05:00-04:00,TROV,negative
1255057.0,60 Biggest Movers From Friday,2019-08-26 05:08:00-04:00,TROV,neutral
1255058.0,The Week Ahead In Biotech: A Quiet One Ahead Of Labor Day Weekend,2019-08-25 15:06:00-04:00,TROV,neutral
1255059.0,42 Stocks Moving In Friday's Mid-Day Session,2019-08-23 14:14:00-04:00,TROV,neutral
1255060.0,8 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-08-23 08:55:00-04:00,TROV,neutral
1255061.0,33 Stocks Moving in Friday's Pre-Market Session,2019-08-23 08:02:00-04:00,TROV,neutral
1255062.0,60 Biggest Movers From Yesterday,2019-08-22 05:12:00-04:00,TROV,neutral
1255063.0,TrovaGene Shares Volatile Ahead of Oncology Presentation,2019-08-21 16:33:00-04:00,TROV,positive
1255064.0,38 Stocks Moving In Wednesday's Mid-Day Session,2019-08-21 12:31:00-04:00,TROV,neutral
1255065.0,25 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-08-21 08:48:00-04:00,TROV,neutral
1255066.0,21 Stocks Moving in Wednesday's Pre-Market Session,2019-08-21 07:47:00-04:00,TROV,neutral
1255067.0,44 Stocks Moving In Tuesday's Mid-Day Session,2019-08-20 12:21:00-04:00,TROV,neutral
1255068.0,22 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-08-20 08:32:00-04:00,TROV,neutral
1255069.0,32 Stocks Moving in Tuesday's Pre-Market Session,2019-08-20 07:49:00-04:00,TROV,neutral
1255070.0,72 Biggest Movers From Yesterday,2019-08-20 05:24:00-04:00,TROV,neutral
1255071.0,48 Stocks Moving In Monday's Mid-Day Session,2019-08-19 13:33:00-04:00,TROV,neutral
1255072.0,33 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-08-19 08:47:00-04:00,TROV,neutral
1255073.0,27 Stocks Moving in Monday's Pre-Market Session,2019-08-19 08:12:00-04:00,TROV,neutral
1255074.0,The Week Ahead In Biotech: FDA Goes Into Overdrive In A Quiet Week,2019-08-17 13:46:00-04:00,TROV,neutral
1255075.0,Trovagene To Present New Data From Onvansertib Phase 2 Study In Metastatic Castration-Resistant Prostate Cancer At Conference,2019-08-15 08:34:00-04:00,TROV,negative
1255076.0,"The Daily Biotech Pulse: Mallinkckrodt's Terlipressin, Deciphera Offering, Sellas Reboots On Earnings",2019-08-15 07:45:00-04:00,TROV,neutral
1255077.0,"The Daily Biotech Pulse: Regeneron's Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics Offering",2019-08-14 07:50:00-04:00,TROV,negative
1255078.0,50 Healthcare Stocks Moving In Thursday's After-Market Session,2019-08-08 21:56:00-04:00,TROV,neutral
1255079.0,"TrovaGene Q2 EPS $(0.79) Misses $(0.53) Estimate, Sales $138K Miss $180K Estimate",2019-08-08 16:48:00-04:00,TROV,negative
1255080.0,"The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index",2019-07-24 07:08:00-04:00,TROV,neutral
1255081.0,List of Companies Reaching Yearly Lows Tuesday,2019-07-23 14:58:00-04:00,TROV,neutral
1255082.0,"The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation",2019-07-23 07:26:00-04:00,TROV,negative
1255083.0,Trovagene Announces Initiation Of Enrollment For Phase 1b/2 Clinical Trial In KRAS-Mutated Colorectal Cancer At Leading Comprehensive Cancer Centers,2019-07-09 08:15:00-04:00,TROV,negative
1255084.0,"The Daily Biotech Pulse: Roche Presents Positive Hemlibra Data, Amgen's Tender Offer For Nuevolution Complete, Genmab Offering",2019-07-09 07:11:00-04:00,TROV,positive
1255085.0,"The Daily Biotech Pulse: Roche's Flu Drug Aces Late-Stage Trial, Acura Outlicenses Pain Medication, Neuronetics Gets New Finance Chief",2019-07-03 07:31:00-04:00,TROV,negative
1255086.0,Trovagene Files For Mixed Shelf Offering,2019-06-25 08:02:00-04:00,TROV,neutral
1255087.0,"The Daily Biotech Pulse: ContraVir's Volatile Ride Continues, Late-Stage Disappointment For Exelixis, Regeneron-Sanofi Breathe Easy",2019-06-21 07:18:00-04:00,TROV,negative
1255088.0,"Trovagene Reports Research Collab With Nektar Therapeutics To Evaluate Efficacy Of Combo Of Onvansertib, ONZEALD In Models Of Colorectal Cancer",2019-05-23 08:06:00-04:00,TROV,negative
1255089.0,Trovagene Oncology Announces $1.5M Investment from Lincoln Park Capital,2019-05-13 08:04:00-04:00,TROV,neutral
1255090.0,"TrovaGene Q1 EPS $(1.02) Beats $(1.07) Estimate, Sales $162K Miss $170K Estimate",2019-05-07 17:49:00-04:00,TROV,negative
1255091.0,35 Stocks Moving In Friday's Pre-Market Session,2019-05-03 08:05:00-04:00,TROV,neutral
1255092.0,60 Biggest Movers From Yesterday,2019-04-25 04:27:00-04:00,TROV,neutral
1255093.0,50 Stocks Moving In Wednesday's Mid-Day Session,2019-04-24 12:42:00-04:00,TROV,neutral
1255094.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Wed., Apr. 24, 2019",2019-04-24 10:16:00-04:00,TROV,positive
1255095.0,24 Stocks Moving In Wednesday's Pre-Market Session,2019-04-24 08:13:00-04:00,TROV,neutral
1255096.0,52 Biggest Movers From Yesterday,2019-04-24 05:11:00-04:00,TROV,neutral
1255097.0,38 Stocks Moving In Tuesday's Mid-Day Session,2019-04-23 13:06:00-04:00,TROV,neutral
1255098.0,Mid-Morning Market Update: Markets Open Higher; Twitter Profit Tops Views,2019-04-23 10:12:00-04:00,TROV,positive
1255099.0,TrovaGene shares are trading higher after the company announced data demonstrating 'Significant Synergy' for its ongoing onvansertib clinical development in combination with Venetoclax.,2019-04-23 08:11:00-04:00,TROV,positive
1255100.0,Trovagene Announces Data Demonstrating 'Significant Synergy' Of Onvansertib In Combination With Venetoclax In Cell Model Of Venetoclax-Resistant AML,2019-04-23 08:03:00-04:00,TROV,positive
1255101.0,24 Stocks Moving In Monday's Pre-Market Session,2019-04-08 08:09:00-04:00,TROV,neutral
1255102.0,54 Biggest Movers From Friday,2019-04-08 05:11:00-04:00,TROV,neutral
1255103.0,40 Stocks Moving In Friday's Mid-Day Session,2019-04-05 12:30:00-04:00,TROV,neutral
1255104.0,Mid-Day Market Update: Crude Oil Up 1%; Aehr Test Systems   Shares Spike Higher,2019-04-05 12:04:00-04:00,TROV,negative
1255105.0,Mid-Morning Market Update: Markets Open Higher; US March Payrolls Exceed Forecasts,2019-04-05 10:28:00-04:00,TROV,neutral
1255106.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Fri., Apr. 5, 2019",2019-04-05 10:03:00-04:00,TROV,positive
1255107.0,TrovaGene shares are trading higher after the company announced a positive data update from its Phase 1b/2 AML trial of onvansertib for patients with Acute Myeloid Leukemia.,2019-04-05 09:14:00-04:00,TROV,positive
1255108.0,UPDATE: Trovagene Reports '~90% clinical benefit acheived - complete response + partial response + stable disease',2019-04-05 08:17:00-04:00,TROV,positive
1255109.0,Trovagene Offers Updated Data From Phase 1b/2 AML Trial Following AACR Meeting: 'Complete response achieved in 3 of 6 (50%) evaluable patients at the highest dose',2019-04-05 08:16:00-04:00,TROV,positive
1255110.0,Trovagene Reports $1.5M Equity Investment At Premium To Market From Lincoln Park Capital,2019-04-05 08:01:00-04:00,TROV,neutral
1255111.0,54 Biggest Movers From Yesterday,2019-04-03 05:42:00-04:00,TROV,neutral
1255112.0,51 Stocks Moving In Tuesday's Mid-Day Session,2019-04-02 12:27:00-04:00,TROV,neutral
1255113.0,32 Stocks Moving In Tuesday's Pre-Market Session,2019-04-02 08:20:00-04:00,TROV,neutral
1255114.0,UPDATE: Trovagene Reports 'Early PSA response observed when onvansertib is added to Zytiga in 2 of 6 patients to-date; first patient achieves primary efficacy endpoint',2019-04-02 08:04:00-04:00,TROV,neutral
1255115.0,Trovagene Highlights Presentation Of Early Data From Ongoing Phase 2 Study Of Onvansertib In Combo With Zytiga For Patients With Metastatic Castration-Resistant Prostate Cancer,2019-04-02 08:03:00-04:00,TROV,negative
1255116.0,58 Biggest Movers From Yesterday,2019-04-02 05:45:00-04:00,TROV,neutral
1255117.0,"Trovagene Shares Resume Trade, Pull Back Slightly From Highs, Stock Still Up 41.9% For Session",2019-04-01 13:17:00-04:00,TROV,positive
1255118.0,"Trovagene Shares Resume Trade, Continue Higher, Now Up 48%; Shares Halted On Second Circuit Breaker",2019-04-01 13:11:00-04:00,TROV,positive
1255119.0,46 Stocks Moving In Monday's Mid-Day Session,2019-04-01 13:06:00-04:00,TROV,neutral
1255120.0,UPDATE: Trovagene Sees Initial Update From Phase 2 Portion Of ProSTAR 2H'19,2019-04-01 13:01:00-04:00,TROV,neutral
1255121.0,UPDATE: Trovagene Says 'Clinical activity of CPI-1205 was seen in subsets of advanced mCRPC patients',2019-04-01 13:01:00-04:00,TROV,positive
1255122.0,Trovagene Highlights Presentation Of Results From Phase 1b ProSTAR Trial Of CPI-1205 At AACR Meeting,2019-04-01 13:00:00-04:00,TROV,neutral
1255123.0,24 Stocks Moving In Monday's Pre-Market Session,2019-04-01 08:14:00-04:00,TROV,neutral
1255124.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs",2019-03-30 09:32:00-04:00,TROV,neutral
1255125.0,71 Biggest Movers From Yesterday,2019-03-15 05:24:00-04:00,TROV,neutral
1255126.0,56 Stocks Moving In Thursday's Mid-Day Session,2019-03-14 12:24:00-04:00,TROV,neutral
1255127.0,Trovagene Receives Approximately $3M From Exercise of Warrants,2019-03-13 08:33:00-04:00,TROV,neutral
1255128.0,56 Biggest Movers From Yesterday,2019-03-13 06:04:00-04:00,TROV,neutral
1255129.0,42 Stocks Moving In Tuesday's Mid-Day Session,2019-03-12 14:06:00-04:00,TROV,neutral
1255130.0,Trovagene Regains Compliance With Nasdaq Listing Requirements,2019-03-12 08:31:00-04:00,TROV,neutral
1255131.0,40 Stocks Moving In Monday's Mid-Day Session,2019-03-11 12:02:00-04:00,TROV,neutral
1255132.0,30 Stocks Moving In Monday's Pre-Market Session,2019-03-11 08:02:00-04:00,TROV,neutral
1255133.0,70 Biggest Movers From Friday,2019-03-11 05:26:00-04:00,TROV,neutral
1255134.0,Mid-Afternoon Market Update: NV5 Global Drops After Q4 Results; Seelos Therapeutics Shares Climb,2019-03-08 14:27:00-05:00,TROV,positive
1255135.0,50 Stocks Moving In Friday's Mid-Day Session,2019-03-08 12:31:00-05:00,TROV,neutral
1255136.0,What's Behind TrovaGene's Volatile Ride?,2019-03-08 12:28:00-05:00,TROV,neutral
1255137.0,Mid-Day Market Update: Crude Oil Down 3%; Stellar Biotechnologies Shares Surge,2019-03-08 12:11:00-05:00,TROV,negative
1255138.0,Mid-Morning Market Update: Markets Open Lower; Big Lots Earnings Top Estimates,2019-03-08 10:17:00-05:00,TROV,negative
1255139.0,8 Biggest Price Target Changes For Friday,2019-03-08 09:35:00-05:00,TROV,neutral
1255140.0,28 Stocks Moving In Friday's Pre-Market Session,2019-03-08 07:54:00-05:00,TROV,neutral
1255141.0,TrovaGene shares are trading higher on continued strength after traders on Thursday circulated word of an FDA abstract document for the company's prostate cancer treatment; analysts at Maxim and Noble Financial reiterated bullish positions on the stock.,2019-03-08 07:43:00-05:00,TROV,positive
1255142.0,"Noble Financial Reiterates Outperform on TrovaGene, Lowers Price Target from $27 to $20",2019-03-08 07:39:00-05:00,TROV,positive
1255143.0,"Benzinga Pro Top 10 Most-Searched Tickers For Morning Of Fri., Mar. 8, 2019",2019-03-08 07:34:00-05:00,TROV,positive
1255144.0,64 Biggest Movers From Yesterday,2019-03-08 05:22:00-05:00,TROV,neutral
1255145.0,"TrovaGene shares are trading higher after traders circulated word of an FDA abstract document for the company's prostate cancer treatment; Maxim reportedly reiterated an $8 price target on the stock, citing 'positive' data on onvansertib.",2019-03-07 13:44:00-05:00,TROV,negative
1255146.0,51 Stocks Moving In Thursday's Mid-Day Session,2019-03-07 12:32:00-05:00,TROV,neutral
1255147.0,"Maxim Reiterates $8 Price Target On Trovagene, Sees 'Positive' Data On Onvansertib Representing A Catalyst For The Stock",2019-03-07 10:32:00-05:00,TROV,neutral
1255148.0,"Trovagene Shares Spike To Session High, Now Up 17%; Traders Circulate Word Of FDA Abstract Doc For Co.'s Prostate Cancer Treatment",2019-03-07 10:02:00-05:00,TROV,negative
1255149.0,"TrovaGene Q4 EPS $(1.09) Misses $(1.05) Estimate, Sales $78K Miss $110K Estimate",2019-03-06 16:23:00-05:00,TROV,negative
1255150.0,75 Biggest Movers From Yesterday,2019-03-01 04:55:00-05:00,TROV,neutral
1255151.0,"Trovagene Reports 1-for-6 Reverse Stock Split, Effective Feb, 19",2019-02-19 08:00:00-05:00,TROV,positive
1255152.0,Trovagene S-3 Shows Registration For For 4M Share Common Stock Offering Via Selling Shareholders,2019-02-14 17:36:00-05:00,TROV,positive
1255153.0,"Trovagene Offers Update On Phase 2 Study Of Onvansertib In Combo With Zytiga In Patients With mCRPC at ASCO-GU Conference: 'Safety lead-in completed, no overlapping toxicities, combination is safe and well tolerated'",2019-02-14 10:30:00-05:00,TROV,positive
1255154.0,"TrovaGene shares trading higher after the company announced an agreement with PoC Capital, which will fund a trial of its Ovansertib colorectal cancer candidate; The company also announced receipt of a 'may proceed' notification from the FDA for trial.",2019-01-29 09:58:00-05:00,TROV,neutral
1255155.0,UPDATE: Trovagene Reported It Received A 'May Proceed' Notification From FDA For Phase 1b/2 Trial Of Ovansertib In Combo With Standard-Of-Care In Patients With mCRC Harboring KRAS Mutations,2019-01-29 08:33:00-05:00,TROV,neutral
1255156.0,"Trovagene Reports Co., PoC Capital Entered Deal To Fund Clinical Development Of Onvansertib In Metastatic Colorectal Cancer",2019-01-29 08:32:00-05:00,TROV,negative
1255157.0,Trovagene Announces New Patent Issued for Combination of Onvansertib with Anti-Androgen Drugs to Treat Non-Metastatic and Metastatic Prostate Cancer,2019-01-23 08:33:00-05:00,TROV,negative
1255158.0,"The Daily Biotech Pulse: Revance Common Stock Offering, Adcom Catalyst For Amgen",2019-01-16 08:24:00-05:00,TROV,neutral
1255159.0,"The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas",2018-12-19 07:46:00-05:00,TROV,positive
1255160.0,"The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan",2018-12-18 08:00:00-05:00,TROV,positive
1255161.0,"The Daily Biotech Pulse: Axovant In-Licenses 2 Gene Therapies, Agile To Undertake Additional Study Of Contraceptive Patch",2018-12-14 07:47:00-05:00,TROV,neutral
1255162.0,"The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs",2018-12-02 17:51:00-05:00,TROV,neutral
1255163.0,"Trovagene Announces Nasdaq Has Granted Co.'s Request For Continued Listing On Nasdaq Capital Market, Subject To Compliance Conditions",2018-11-15 08:35:00-05:00,TROV,positive
1255164.0,"TrovaGene Q3 EPS $(0.18) Beats $(0.33) Estimate, Sales $88K Miss $100K Estimate",2018-11-07 17:49:00-05:00,TROV,negative
1255165.0,Trovagene Announces the US Patent and Trademark Office Has Allowed Claims that Affirm Broad Coverage of NPM1,2018-10-24 08:31:00-04:00,TROV,neutral
1255166.0,"The Daily Biotech Pulse: Illumina's Strong Q3, Celgene's Positive Cancer Drug Trial, Proteostasis Offering",2018-10-24 07:48:00-04:00,TROV,positive
1255167.0,"Trovagene To Offers Update On Ovansertib Clinical Development Program Wed., Oct. 24, 2018",2018-10-18 08:34:00-04:00,TROV,neutral
1255168.0,Trovagene Announces Exclusive License Agreement With MIT For Combination Therapy Of Anti-Androgens And Polo-like Kinase Inhibitors In Prostate Cancer,2018-10-03 08:32:00-04:00,TROV,negative
1255169.0,Trovagene Reports Completion Of Dosing Cohort Of Patients Treated With Onvansertib In Combo With Decitabine In Ongoing Phase 1b/2 AML Trial,2018-09-27 08:33:00-04:00,TROV,positive
1255170.0,Trovagene Reports It Has Developed Method For Predicting Response To Treatment By Measuing Ability Of Onvansertib To Inhibit PLK1 In Patients With Acute Myeloid Leukemia,2018-09-05 08:25:00-04:00,TROV,negative
1255171.0,Trovagene Announces European Commission Grants Orphan Drug Designation to Onvansertib,2018-08-29 08:34:00-04:00,TROV,positive
1255172.0,Trovagene Announces Completion of Second Dosing Cohort of Patients Treated with Onvansertib,2018-08-16 08:00:00-04:00,TROV,neutral
1255173.0,"Trovagene Receives USAN Approval For Onvansertib As Nonproprietary Name For First-In-Class, 3rd Generation PLK1 Inhibitor Drug Candidate, PCM-075",2018-08-15 08:01:00-04:00,TROV,positive
1255174.0,"TrovaGene Q2 EPS $(0.44) Misses $(0.33) Estimate, Sales $112K Beat $110K Estimate",2018-08-03 17:16:00-04:00,TROV,negative
1255175.0,"Trovagene Shares Down 6% Amid Positive Opinion For PCM-075 In European Union; BZ NOTE On Decline In Stock Price Following Positive News: Shares Rallied 6% Into Tues. Close Amid No News, Prior To PCM-075 News, Stock Now At Same Level As Tues. Close",2018-08-01 10:22:00-04:00,TROV,positive
1255176.0,Trovagene Shares Up 7% Premarket As Co. Reports Received Positive Opinion For Orphan Drug Designation In European Union For PCM-075,2018-08-01 08:12:00-04:00,TROV,positive
1255177.0,"Stocks Which Set New 52-Week Low Yesterday, July 26th:",2018-07-27 10:54:00-04:00,TROV,negative
1255178.0,"Benzinga's Daily Biotech Pulse: Achaogen To Trim Workforce By 28%, Amgen's Beat-And-Raise Quarter",2018-07-27 08:44:00-04:00,TROV,neutral
1255179.0,Trovagene Presents Outlook for Second Half of 2018,2018-07-09 08:05:00-04:00,TROV,neutral
1255180.0,"Benzinga's Daily Biotech Pulse: Realm Therapeutics To List On Nasdaq, CASI Pharma Added To Russell 2000 Index",2018-07-05 07:43:00-04:00,TROV,neutral
1255181.0,"Benzinga's Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos",2018-06-29 08:11:00-04:00,TROV,positive
1255182.0,UPDATE: Trovagene Says 'pharmacodynamic data supports inhibition of PLK1 in leukemic cells as measured by pTCTP in its Phase 1b/2 trial in Acute Myeloid Leukemia',2018-06-27 08:19:00-04:00,TROV,neutral
1255183.0,Trovagene Reports Prelim. Data From First Dosing Cohort Showing Durable Treatment Effect Of PCM-075 In Combo with Cytarabine Or Decitabine In Patients With Relapsed Or Refractory AML,2018-06-27 08:18:00-04:00,TROV,positive
1255184.0,"A Peek Into The Markets: US Stock Futures Drop, Dow Futures Down Over 150 Points",2018-06-25 07:24:00-04:00,TROV,negative
1255185.0,"6 Stocks To Watch For June 25, 2018",2018-06-25 04:25:00-04:00,TROV,neutral
1255186.0,"Trovagene CEO William Welch Steps Down For Personal Reasons, Effective Immediately, Dr. Thomas Adams Will Serve In The Interim As A Search Is Conducted",2018-06-22 17:22:00-04:00,TROV,positive
1255187.0,"Trovagene Reports the Start of Recruitment, Enrollment for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga",2018-06-21 08:02:00-04:00,TROV,neutral
1255188.0,Maxim Group Upgrades TrovaGene to Buy,2018-06-15 14:20:00-04:00,TROV,neutral
1255189.0,UPDATE: Trovagene Highlights Safety Review Committee Has Recommended Proceeding To Second Dosing Cohort In PCM-075 Combo Trial,2018-06-15 08:13:00-04:00,TROV,positive
1255190.0,Trovagene Reports Completion Of First Dosing Cohort Of Patients Treated With PCM-075 In Combo With Decitabine In Ongoing Phase 1b/2 AML Trial,2018-06-15 08:13:00-04:00,TROV,positive
1255191.0,"Benzinga's Daily Biotech Pulse: EDAP Device Gets FDA Nod, Ampliphi Presents Positive Data, Agile To Cut Jobs",2018-06-08 09:20:00-04:00,TROV,positive
1255192.0,Trovagene Prices 18M Share Public Offering of Stocks and Warrants @$1.00/Share and Warrant,2018-06-08 03:58:00-04:00,TROV,positive
1255193.0,"Benzinga's Daily Biotech Pulse: Johnson & Johnson to Dispose Sterilization Products Business, Mixed Results From Protesostasis' Cystic Fibrosis Study",2018-06-07 07:58:00-04:00,TROV,neutral
1255194.0,40 Biggest Movers From Yesterday,2018-06-07 04:50:00-04:00,TROV,neutral
1255195.0,"Benzinga's Daily Biotech Pulse: Vascular Biogenics Soars On Positive Platform Data, Axovant Licenses Parkinson's Candidate",2018-06-06 08:38:00-04:00,TROV,positive
1255196.0,45 Biggest Movers From Yesterday,2018-06-06 04:35:00-04:00,TROV,neutral
1255197.0,35 Stocks Moving In Tuesday's Mid-Day Session,2018-06-05 12:25:00-04:00,TROV,neutral
1255198.0,"Benzinga Pro's Top 10 Most-Searched Tickers For The Evening Of Mon., Jun. 4",2018-06-04 16:44:00-04:00,TROV,positive
1255199.0,"Trovagene, Inc. Announces 1-for-12 Reverse Stock Split Effective June 1",2018-05-31 17:00:00-04:00,TROV,positive
1255200.0,"TrovaGene Q1 EPS $(0.09) Beats $(0.12) Estimate, Sales Met $100K Estimate",2018-05-08 16:29:00-04:00,TROV,neutral
1255201.0,"Trovagene Reports PCM-075 Combo With Quizartinib Resulted In 97% Tumor Growth Inhibition, Regression In FLT3 AML Model; Data Presented At AACR Meeting",2018-04-16 09:04:00-04:00,TROV,positive
1255202.0,"Trovagene Shares Spike Over $0.40 Level, Now Up 15% For Session; Not Seeing Mid-Day News To Justify Price Action",2018-03-13 14:57:00-04:00,TROV,positive
1255203.0,Trovagene Shares Up 16.2% Premarket After Co. Announced First Patient Successfully Completed Cycle 1 Of Treatment With PCM-075,2018-03-05 08:54:00-05:00,TROV,positive
1255204.0,Trovagene Announces First Patient Successfully Completes Cycle 1 of Treatment with PCM-075 in Combination with Low Dose Cytarabine (LDAC) in AML Trial,2018-03-05 08:07:00-05:00,TROV,positive
1255205.0,"Trovagene Reports Q4 EPS $(0.06) vs $(0.34) In Same Qtr. Last Year, Sales $185K vs $68K YoY",2018-02-26 17:35:00-05:00,TROV,neutral
1255206.0,UPDATE: Trovagene Says 'Yale Cancer Center and Kansas University Cancer Center now actively screening and enrolling patients in Phase 1b/2 Study of PCM-075 in AML,2018-02-13 08:09:00-05:00,TROV,negative
1255207.0,Trovagene Reports Activation Of 2 Added Clinical Trial Sites To Conduct Its Phase 1b/2 Study Of PCM-075 In Patients With AML,2018-02-13 08:08:00-05:00,TROV,positive
1255208.0,TrovaGene Shares Down 8.3% On Potential Profit Taking; Friday Shares Rose As Much As 37% After Encouraging Presentation of Data For PCM-075,2018-02-12 14:45:00-05:00,TROV,positive
1255209.0,44 Biggest Movers From Friday,2018-02-12 05:01:00-05:00,TROV,neutral
1255210.0,Trovagene Presents Data Showing Synergy of PCM-075 in Combination with Zytiga® in Castration-Resistant Prostate Cancer Model at 2018 Genitourinary Cancers Symposium,2018-02-09 15:16:00-05:00,TROV,negative
1255211.0,Trovagene Initiates UNITE Phase 2 Trial Of PCM-075 In Patients With mCRPC,2018-01-24 08:05:00-05:00,TROV,neutral
1255212.0,"Benzinga's Top Upgrades, Downgrades For December 21, 2017",2017-12-21 09:30:00-05:00,TROV,positive
1255213.0,Trovagene Reports Activation Of Second Trial Site In Phase 1b/2 AML Trial For PCM-075,2017-12-21 08:01:00-05:00,TROV,positive
1255214.0,33 Biggest Movers From Friday,2017-12-18 05:45:00-05:00,TROV,neutral
1255215.0,Mid-Afternoon Market Update: Dow Surges Over 150 Points; Longfin Shares Spike Higher,2017-12-15 14:33:00-05:00,TROV,positive
1255216.0,30 Stocks Moving In Friday's Mid-Day Session,2017-12-15 12:30:00-05:00,TROV,neutral
1255217.0,Mid-Day Market Update: ShiftPixy Gains Following Q4 Results; Verastem Shares Plummet,2017-12-15 12:19:00-05:00,TROV,positive
1255218.0,Mid-Morning Market Update: Markets Open Higher; Adobe Earnings Top Expectations,2017-12-15 10:11:00-05:00,TROV,positive
1255219.0,25 Stocks Moving In Friday's Pre-Market Session,2017-12-15 08:27:00-05:00,TROV,neutral
1255220.0,Trovagene Prices 15M Share Common Stock Offering At $0.30/Share,2017-12-15 06:01:00-05:00,TROV,positive
1255221.0,Trovagene Submits Protocol to FDA for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga,2017-12-14 08:01:00-05:00,TROV,neutral
1255222.0,"Trovagene Shares Indicated Higher After Hours Thurs. As Co. Issues Release Highlighting Data In SABCS 'Showing Sensitivity Of Triple Negative Breast Cancer Cell Lines To PCM-075, Synergy with Zytiga'",2017-12-07 17:05:00-05:00,TROV,negative
1255223.0,Maxim Group Downgrades TrovaGene to Hold,2017-11-10 07:55:00-05:00,TROV,neutral
1255224.0,"Trovagene Issues Release Highlighting Earlier-Issued (Via 8-K) Q3 Results: EPS $(0.12) vs $(0.14) Est., Sales $123K vs $89K In Same Qtr. Last Year",2017-11-09 10:35:00-05:00,TROV,neutral
1255225.0,Trovagene S-1 Filing Shows Registration For $17.5M Mixed Securities Shelf Offering,2017-10-25 16:34:00-04:00,TROV,positive
1255226.0,Trovagene Reports Data From Preclinical Research Demonstrating Synergy Of PCM-075 With Zytiga,2017-10-18 08:06:00-04:00,TROV,neutral
1255227.0,Secondary Offering Lockup Expirations Today For Westport Fuel Systems and TrovaGene,2017-10-12 08:50:00-04:00,TROV,neutral
1255228.0,Trovagene Reports FDA Orphan Drug Designation For PCM-075 For Treatment Of AML,2017-10-09 08:01:00-04:00,TROV,positive
1255229.0,Secondary Offering Lockup Expirations For Akebia Therapeutics and Trovagene,2017-09-27 09:07:00-04:00,TROV,neutral
1255230.0,Trovagene Reports PLK1 Inhibitor PCM-075 Significantly Enhances the Efficacy of a FLT3 inhibitor in Combination Therapy,2017-08-16 08:02:00-04:00,TROV,negative
1255231.0,"Trovagene Reports Q2 EPS $(0.26) vs $(0.15) Est., Sales $102K vs $104K In Same Qtr. Last Year",2017-08-09 16:30:00-04:00,TROV,neutral
1255232.0,Trovagene Reports FDA Approval Of IND For Phase 1b/2 Trial Of PCM-075 In Patients With AML,2017-07-27 08:23:00-04:00,TROV,positive
1255233.0,Trovagene Announces FDA Approval of IND for Phase 1b/2 Trial of PCM-075 in Patients with Acute Myeloid Leukemia,2017-07-27 08:13:00-04:00,TROV,positive
1255234.0,Trovagene Reports Peer-Reviewed Publication of First-in-Human Phase 1 Trial Results with PCM-075,2017-07-25 08:08:00-04:00,TROV,neutral
1255235.0,CVI Investments Shows a 5.7% Passive Stake in Trovagene,2017-07-24 07:52:00-04:00,TROV,positive
1255236.0,13G Filing From Sabby Mgmt. On Trovagene Shows New 5.7% Stake,2017-07-17 15:01:00-04:00,TROV,neutral
1255237.0,Trovagene Reports $7.1M Registered Direct Offering,2017-07-14 09:00:00-04:00,TROV,neutral
1255238.0,Trovagene Reports Engaged The Leading Global Contract Research Organization To Conduct Phase 1b/2 Trial Of PCM-075,2017-07-06 08:10:00-04:00,TROV,positive
1255239.0,Trovagene Reports Deal With NerPharMa For Supply Of PCM-075 For AML Trial,2017-06-29 08:03:00-04:00,TROV,positive
1255240.0,"Trovagene Shares Up 13.5% No New News Wed.; Co. Announced 2 News Items Over Last 2 Days: Submission Of IND For FDA Approval Of PCM-075, Expansion Of Claims For NPM1 Patent Portfolio",2017-06-28 13:52:00-04:00,TROV,positive
1255241.0,Trovagene Reports Submission Of IND Application To Initiate Phase 1b/2 Trial Of PCM-075 For Acute Myeloid Leukemia,2017-06-27 08:02:00-04:00,TROV,neutral
1255242.0,Trovagene REports Expansion of Key Claims for its NPM1 Patent Portfolio for Acute Myeloid Leukemia,2017-06-26 08:03:00-04:00,TROV,neutral
1255243.0,"Trovagene Shares Volatile After Hours, Indicated Up ~4%; Likely Trading In Sympathy With Idera, Up 14% On FDA Orphan Drug News",2017-06-22 16:51:00-04:00,TROV,positive
1255244.0,"Trovagene Reports Agreement With Undisclosed Biopharmaceutical Company To Utilize Trovera ctDNA Tests, Services In Cancer Clinical Trials",2017-06-22 08:02:00-04:00,TROV,negative
1255245.0,Mid-Afternoon Market Update: Coherus Biosciences Drops After FDA Response Letter; TrovaGene Shares Surge,2017-06-12 14:30:00-04:00,TROV,positive
1255246.0,15 Biggest Mid-Day Gainers For Monday,2017-06-12 12:44:00-04:00,TROV,neutral
1255247.0,Mid-Day Market Update: Crude Oil Up 1%; GTx Shares Spike Higher,2017-06-12 12:03:00-04:00,TROV,negative
1255248.0,Mid-Morning Market Update: Markets Open Lower; General Electric CEO To Step Down,2017-06-12 10:11:00-04:00,TROV,negative
1255249.0,"Trovagene Reports Deal With AstraZeneca For Utilization Of Trovera ctDNA Test, Services In Prospective Biomarker Study",2017-06-12 08:05:00-04:00,TROV,neutral
1255250.0,Trovagene Phase 1 Safety Supports Planned Development of PCM-075 In AML,2017-05-25 08:04:00-04:00,TROV,positive
1255251.0,"Trovagene Reports Q1 EPS $(0.32) vs $(0.24) Est., Sales $95K vs $120K In Prior Year Period",2017-05-10 16:37:00-04:00,TROV,neutral
1255252.0,"Shares of Trovagene Up 13%, Hearing Maxim Upgrades Trovagene To Buy",2017-04-12 12:28:00-04:00,TROV,positive
1255253.0,15 Biggest Mid-Day Losers For Wednesday,2017-03-22 13:02:00-04:00,TROV,negative
1255254.0,Mid-Afternoon Market Update: Oracle Gains On Earnings Beat; TrovaGene Shares Slide,2017-03-16 15:23:00-04:00,TROV,positive
1255255.0,18 Biggest Mid-Day Losers For Thursday,2017-03-16 13:10:00-04:00,TROV,negative
1255256.0,Mid-Day Market Update: U.S. Stocks Turn Negative; GoPro Shares Spike Higher,2017-03-16 12:17:00-04:00,TROV,negative
1255257.0,Mid-Morning Market Update: Markets Open Higher; Dollar General Beats Q4 Expectations,2017-03-16 10:09:00-04:00,TROV,neutral
1255258.0,PiperJaffray Downgrades TrovaGene To Underweight,2017-03-16 07:17:00-04:00,TROV,neutral
1255259.0,"Trovagene Reports Q4 EPS $(0.34) vs. $(0.32) Est., Sales $68K vs. $180K Est.",2017-03-15 16:04:00-04:00,TROV,neutral
1255260.0,Trovagene & Nerviano Announce License Agreement For Therapeutic Candidate PCM-075,2017-03-15 16:03:00-04:00,TROV,positive
1255261.0,Trovagene Reports Publication of Trovera KRAS Liquid Biopsy Test Showed Clinical Utility in Advanced Cancers for Detection and Measurement of Therapeutic Response,2017-01-24 08:05:00-05:00,TROV,positive
1255262.0,18 Biggest Mid-Day Losers For Wednesday,2016-12-14 12:56:00-05:00,TROV,negative
1255263.0,20 Stocks Moving In Wednesday's Pre-Market Session,2016-12-14 08:36:00-05:00,TROV,neutral
1255264.0,"UPDATE: Trovagene Says Will Increase Focus on Global Distribution of Kits, Systems to Clinical Research Labs for Liquid Biopsy Oncology Testing Market",2016-12-13 16:07:00-05:00,TROV,positive
1255265.0,Trovagene Reports Reorganization,2016-12-13 16:07:00-05:00,TROV,neutral
1255266.0,Trovagene and Boreal Genomics Announce Strategic Partnership,2016-11-30 08:02:00-05:00,TROV,negative
1255267.0,"Trovagene, Inc.: MIGNONE ROBERTO (10%+) Buys 322,472 @ Avg Price: $3.08 (Form4",2016-11-15 14:33:00-05:00,TROV,neutral
1255268.0,Trovagene Reports Q3 EPS $(0.34) vs $(0.29) Est.,2016-11-09 16:56:00-05:00,TROV,neutral
1255269.0,"Trovagene Announces U.S. Patent and Trademark Office has Issued Patent No 9,453,265 Entitled 'Method for Detection of High Risk Human Papillomavirus'",2016-11-07 08:28:00-05:00,TROV,negative
1255270.0,Trovagene Selected by Pancreatic Cancer Action Network as Liquid Biopsy Provider to Participate in Precision Promise,2016-10-04 06:06:00-04:00,TROV,negative
1255271.0,Trovagene Releases Investor Presentation,2016-09-26 06:12:00-04:00,TROV,neutral
1255272.0,Maxim Issues Mid-Day Note on Trovagene: 'We continue to see Trovagene as the go-to company in detection,2016-08-17 12:26:00-04:00,TROV,neutral
1255273.0,Trovagene Reports BCBS Illinois Will Cover Trovera Liquid Biopsy Tests,2016-08-17 08:32:00-04:00,TROV,neutral
1255274.0,8 Biggest Price Target Changes For Monday,2016-08-08 09:58:00-04:00,TROV,neutral
1255275.0,"Cantor Fitzgerald Upgrades Trovagene To Buy, Bullish On Clinical Business",2016-08-08 09:14:00-04:00,TROV,neutral
1255276.0,Cantor Fitzgerald Upgrades TrovaGene to Buy,2016-08-08 07:21:00-04:00,TROV,neutral
1255277.0,"Trovagene Reports Q2 EPS $(0.34) vs $(0.31) Est., Sales $104K vs $270K Est.",2016-08-04 17:17:00-04:00,TROV,neutral
1255278.0,"Trovagene, USC Norris Comprehensive Cancer Center Partner For Standard Use Of Trovera ctDNA Liquid Biopsy Tests In Patient Care",2016-07-12 08:33:00-04:00,TROV,negative
1255279.0,Trovagene and University of Michigan Enter into Collaboration for Monitoring and Early Detection of Pancreatic Cancer,2016-07-06 10:00:00-04:00,TROV,negative
1255280.0,Trovagene's Liquid Biopsy Urine Test Detects EGFR T790M Mutations in Patients with Non-Small Cell Lung Cancer,2016-06-06 11:01:00-04:00,TROV,negative
1255281.0,Trovagene Files for Up to $250M Mixed Shelf,2016-05-27 17:34:00-04:00,TROV,neutral
1255282.0,8-K from Trovagene Shows William Welch Named CEO,2016-05-18 16:36:00-04:00,TROV,neutral
1255283.0,Mid-Afternoon Market Update: Dow Tumbles 1%; Nordstrom Shares Down Following Earnings Miss,2016-05-13 14:33:00-04:00,TROV,positive
1255284.0,Trovagene Announces Large Clinical Study Shows High Detection Rate and Ability to Monitor KRAS Mutations in Pancreatic Cancer Patients,2016-05-13 08:06:00-04:00,TROV,negative
1255285.0,"Trovagene Reports Q1 EPS $(0.36) vs. Est. $(0.29), Rev. $120K vs. Est. $260K",2016-05-10 16:10:00-04:00,TROV,neutral
1255286.0,Antonius Schuh Resigns as Member of Trovogene Board of Directors,2016-04-27 17:21:00-04:00,TROV,negative
1255287.0,Cantor Fitzgerald Downgrades TrovaGene to Hold,2016-04-26 07:08:00-04:00,TROV,neutral
1255288.0,Leerink Swann Downgrades TrovaGene to Sector Perform,2016-04-26 05:58:00-04:00,TROV,neutral
1255289.0,Departure Of TrovaGene CCO Creates Near-Term Risks; Cantor Downgrades Stock,2016-04-25 16:53:00-04:00,TROV,neutral
1255290.0,Mid-Afternoon Market Update: Crude Oil Down 2%; KKR Shares Slide Following Q1 Results,2016-04-25 14:31:00-04:00,TROV,negative
1255291.0,Mid-Day Market Update: Tribune Publishing Jumps Following Gannett's Takeover Proposal; TrovaGene Shares Drop,2016-04-25 12:02:00-04:00,TROV,neutral
1255292.0,"Cantor Fitzgerald Says New CEO A Positive, But CCO Departure Creates Near-Term Risks Downgrades Trovagene To Hold With $5 Price Target",2016-04-25 10:35:00-04:00,TROV,positive
1255293.0,Hearing Cantor Fitzgerald Downgrades TrovaGene to Hold in Mid-Day Note,2016-04-25 10:33:00-04:00,TROV,neutral
1255294.0,Mid-Morning Market Update: Markets Open Lower; Xerox Profit Misses Views,2016-04-25 10:06:00-04:00,TROV,negative
1255295.0,Trovagene Names Bill Welch as CEO,2016-04-25 08:05:00-04:00,TROV,neutral
1255296.0,Trovagene Gains 3% On Favorable Mention In Medical Journal,2016-04-15 14:02:00-04:00,TROV,positive
1255297.0,Trovagene Announces Patient Case Report Usings Precision Cancer Monitoring Technology,2016-04-15 08:16:00-04:00,TROV,negative
1255298.0,TrovaGene Stikes A Preferred Provider Deal With Stratose,2016-04-11 09:12:00-04:00,TROV,neutral
1255299.0,Trovagene Reports Entered Into Preferred Provider Deal with Stratose PPO Network,2016-04-11 08:15:00-04:00,TROV,neutral
1255300.0,TrovaGene To Present Clinical Data On Its Precision Cancer Monitoring Platform,2016-04-07 06:58:00-04:00,TROV,negative
1255301.0,Trovagene Announces Clinical Data Featuring Trovagene's Precision Cancer Monitoring Platform to be Presented at the Molecular DX Europe Conference,2016-04-07 06:11:00-04:00,TROV,negative
1255302.0,"Bridger Management, LLC Reports 11% Stake in Trovagene in 13D",2016-04-05 10:04:00-04:00,TROV,neutral
1255303.0,10 Stocks Moving In Tuesday's Pre-Market Session,2016-03-29 08:25:00-04:00,TROV,neutral
1255304.0,"TrovaGene Down 40% Following Termination Of CEO, CFO",2016-03-29 08:01:00-04:00,TROV,neutral
1255305.0,"Avondale Partners Maintains Market Perform on TrovaGeneto Market Perform, Removes $6.00 PT Citing Lack of Visibility For Co In Lieu Of CEO/CFO Departure",2016-03-29 06:21:00-04:00,TROV,negative
1255306.0,"Trovogene Shares Fall 50% After Hours Following Announcement of Termination of CEO, CFO",2016-03-28 20:43:00-04:00,TROV,positive
1255307.0,"UPDATE: Trovagene Alleges Schuh, Zaniboni Used Promising New Therapeutics in the Field of Precision Medicine for their own Personal Benefit",2016-03-28 19:36:00-04:00,TROV,positive
1255308.0,"Trovagene Terminates Employment of CEO Antonius Schuh, CFO Stephen Zaniboni for Cause",2016-03-28 19:31:00-04:00,TROV,neutral
1255309.0,Mid-Afternoon Market Update: Dow Jumps 200 Points; Bojangles Shares Climb Following Upbeat Earnings,2016-03-11 14:26:00-05:00,TROV,positive
1255310.0,Mid-Day Market Update: Finisar Gains On Earnings Beat; FXCM Shares Drop,2016-03-11 12:05:00-05:00,TROV,positive
1255311.0,Mid-Morning Market Update: Markets Open Higher; Hibbett Sports Q4 Earnings Top Expectations,2016-03-11 09:56:00-05:00,TROV,positive
1255312.0,Janney Capital Downgrades TrovaGene to Neutral,2016-03-11 08:51:00-05:00,TROV,neutral
1255313.0,Trovagene Reports Q4 EPS $(0.26) vs. Est. $(0.25),2016-03-10 16:14:00-05:00,TROV,neutral
1255314.0,Trovagene Spikes to High of $6.66 on Volume,2016-03-04 11:56:00-05:00,TROV,neutral
1255315.0,"Trovagene Enters Into Preferred Provider Agreement with Multiplan, Inc.",2016-03-01 08:16:00-05:00,TROV,positive
1255316.0,Trovagene Announces Entered Into Preferred Provider Deal with Fortified Provider Network,2016-02-22 08:17:00-05:00,TROV,neutral
1255317.0,Trovagene Spikes to High of $3.97 on Volume,2016-02-09 15:18:00-05:00,TROV,neutral
1255318.0,Here's Why Shares Of TrovaGene Are Surging,2016-02-01 10:31:00-05:00,TROV,positive
1255319.0,Trovagene Announces Agreement with FedMed,2016-02-01 04:12:00-05:00,TROV,positive
1255320.0,Option Alert: TROV Jul16 2.5 Calls Sweep: 500 @  ASK  $1.90: 500 traded vs 242 OI:  Earnings 3/10  $3.91 Ref,2016-01-27 13:14:00-05:00,TROV,positive
1255321.0,Spike in Trovagene May Attributed to Tweet from Co,2016-01-21 12:38:00-05:00,TROV,neutral
1255322.0,Trovagene Spikes to High on Volume,2016-01-21 12:34:00-05:00,TROV,neutral
1255323.0,"Avondale Partners Initiates Coverage on TrovaGene at Market Perform, Announces $6.00 PT",2016-01-06 18:08:00-05:00,TROV,neutral
1255324.0,Mid-Afternoon Market Update: Dow Jumps Over 150 Points; Steelcase Shares Dip Following Weak Results,2015-12-22 14:59:00-05:00,TROV,negative
1255325.0,Option Alert: $TROV Jan $7.5 Call; 628 Contracts @$0.45,2015-11-17 13:11:00-05:00,TROV,positive
1255326.0,Trovagene Reports Q3 EPS $(0.23) vs. Est. $(0.27),2015-11-09 16:09:00-05:00,TROV,neutral
1255327.0,Trovagene's Urine-Based Liquid Biopsy Platform Shows Clinical Sensitivity of 93 Percent in Lung Cancer Study,2015-10-27 08:15:00-04:00,TROV,negative
1255328.0,Practical Clinical Benefits of Trovagene's Urine-Based Liquid Biopsy Platform Showed in Field Experience Analysis,2015-10-08 16:06:00-04:00,TROV,positive
1255329.0,Trovagene Offers Results from Second Large-Scale Trial of Urine-Based HPV Test: Results Compared to Roche's cobas HPV Test,2015-09-21 08:07:00-04:00,TROV,neutral
1255330.0,"Cantor Says Trovagene's Liquid Biopsies Have '10x The Kick,' Is Buying In",2015-09-16 14:22:00-04:00,TROV,neutral
1255331.0,"Cantor Fitzgerald Initiates Coverage on TrovaGene at Buy, Announces $10.00 PT",2015-09-15 17:48:00-04:00,TROV,neutral
1255332.0,Trovagene Forms European Subsidiary Trovagene Research Institute,2015-09-10 04:28:00-04:00,TROV,neutral
1255333.0,Trovagene's Urine-Based Liquid Biopsy Platform Shown to Detect Impact of Cancer Therapy within 24 Hours,2015-09-09 08:10:00-04:00,TROV,negative
1255334.0,Trovagene to Present Clinical Data and Capabilities of Its Urine-Based Liquid Biopsy Platform at the 7th Annual Next Generation Dx Summit,2015-08-18 08:06:00-04:00,TROV,negative
1255335.0,Benzinga's Top Initiations,2015-08-14 10:12:00-04:00,TROV,positive
1255336.0,Leerink: Trovagene Is A Pure Play That Should Outperform,2015-08-14 09:18:00-04:00,TROV,positive
1255337.0,"Leerink Swann Initiates Coverage on TrovaGene at Outperform, Announces $9.00 PT",2015-08-14 08:07:00-04:00,TROV,neutral
1255338.0,"Trovagene CFO Zaniboni Buys 15,000 Shares @$5.43/Share -Form 4",2015-08-12 14:39:00-04:00,TROV,positive
1255339.0,Trovagene Reports Q2 EPS $(0.41) vs. Est. $(0.24),2015-08-10 16:19:00-04:00,TROV,neutral
1255340.0,"Market Update: Google & Hertz Among Mid-Day Movers, Germany Votes In Favor Of Greece Bailout And More",2015-07-17 12:16:00-04:00,TROV,positive
1255341.0,Morning Market Losers,2015-07-17 10:01:00-04:00,TROV,negative
1255342.0,Trovagene Prices Offering of 4M Shares At $8.75/Share,2015-07-17 09:05:00-04:00,TROV,positive
1255343.0,Trovagene Inc Reports Public Offering Of 4 Million Shares Of Common Stock; Gross Proceeds Expected To Be $35M,2015-07-17 09:02:00-04:00,TROV,negative
1255344.0,Trovagene Reports Proposed Offering,2015-07-16 16:32:00-04:00,TROV,neutral
1255345.0,Trovagene Begins Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform,2015-07-08 08:10:00-04:00,TROV,negative
1255346.0,Trovagene to Offer Clinical Data on Co.'s Urine-Based Liquid Biopsy Platform at Two Upcoming Conferences,2015-06-08 08:10:00-04:00,TROV,neutral
1255347.0,Trovagene Trading Resumed,2015-05-01 11:44:00-04:00,TROV,neutral
1255348.0,Trovagene Trading Halted,2015-05-01 11:43:00-04:00,TROV,neutral
1255349.0,Trovagene Shares Spike Higher; Hearing Positive Altucher Comments,2015-05-01 11:42:00-04:00,TROV,positive
1255350.0,Pharmacological Advancements in Neuroscience Drug Discovery & Pre-Clinical Studies for Fragile X Syndrome to Identify Drug Candidates for Autism Therapies Lead Biotech Sector Research,2015-04-20 08:38:00-04:00,TROV,neutral
1255351.0,UPDATE: Trovagene Shares Rise 23% Following Announcement of Positive Data for Urine-based Precision Cancer Monitoring Platform,2015-04-17 11:33:00-04:00,TROV,positive
1255352.0,"Janney Capital Initiates Coverage on TrovaGene at Buy, Announces $11.00 PT",2015-04-02 06:16:00-04:00,TROV,neutral
1255353.0,9 Management Changes From The Past Week,2015-03-20 17:04:00-04:00,TROV,neutral
1255354.0,Stocks Hitting 52-Week Highs,2015-03-18 10:08:00-04:00,TROV,neutral
1255355.0,Trovagene Names Matthew Posard Chief Commercial Officer,2015-03-18 08:32:00-04:00,TROV,neutral
1255356.0,Trovagene Reports Q4 EPS $(0.25) vs. Est. ($0.26),2015-03-12 16:17:00-04:00,TROV,neutral
1255357.0,"Piper Jaffray Initiates Coverage on TrovaGene at Overweight, Announces $6.25 PT",2015-02-17 06:28:00-05:00,TROV,negative
1255358.0,TrovaGene Announces Clinical Results Show High Sensitivity of Urine-Based HPV Assay for Detection of High Risk HPV,2015-02-09 08:13:00-05:00,TROV,negative
1255359.0,TrovaGene Falls Sharply; Prices Offering Below Expectations,2015-02-06 12:57:00-05:00,TROV,neutral
1255360.0,"Friday Morning Movers: GoPro, Twitter Move In Opposite Directions",2015-02-06 11:10:00-05:00,TROV,neutral
1255361.0,Morning Market Losers,2015-02-06 09:56:00-05:00,TROV,negative
1255362.0,Trovagene Announces Pricing of $20M Public Offering of Common Stock,2015-02-06 08:29:00-05:00,TROV,neutral
1255363.0,Trovagene Announces Public Offering of Common Stock,2015-02-05 16:11:00-05:00,TROV,neutral
1255364.0,Clinical Study Results Presented at the 2015 Gastrointestinal Cancer Symposium Support Utility of Trovagene's Precision Cancer Monitoring Platform in Colorectal and Pancreatic Cancer Patients,2015-01-20 08:19:00-05:00,TROV,negative
1255365.0,Trovagene Releases Clinical Study Results For The Detection And Monitoring Of KRAS Mutations,2014-11-20 09:11:00-05:00,TROV,neutral
1255366.0,"Trovagene IR Says No News to Account for Move in Share Price Today, Attributes to Buyer of Co's Stock",2014-08-18 18:43:00-04:00,TROV,neutral
1255367.0,Morning Market Movers ,2014-08-18 09:45:00-04:00,TROV,neutral
1255368.0,"Maxim Group Initiates Coverage on TrovaGene, Inc. at Buy, Announces $10.00 PT",2014-07-09 17:17:00-04:00,TROV,neutral
1255369.0,Trovagene Secures $15 Million in Debt Financing From Silicon Valley Bank And Oxford Finance,2014-07-01 08:06:00-04:00,TROV,negative
1255370.0,"Corporate Events for the Week of Jun. 2nd, 2014",2014-06-02 18:19:00-04:00,TROV,neutral
1255371.0,Trovagene Announces Positive Results From Oncogen Mutation,2014-06-02 12:48:00-04:00,TROV,positive
1255372.0,"Trovagene, US Oncology Research Announce Clinical Study Agreement",2014-01-06 05:40:00-05:00,TROV,positive
1255373.0,"Aegis Capital Reiterates on TrovaGene Following In-Line Revenue, Below-Estimates EPS",2013-11-15 11:09:00-05:00,TROV,neutral
1255374.0,"TrovaGene, Inc. Reports Q3 EPS of $(0.25) vs $(0.22) Est; Revenue of $44.0K vs $470.0K Est",2013-11-14 16:01:00-05:00,TROV,neutral
1255375.0,UPDATE: Aegis Capital Reiterates on TrovaGene Ahead of 3Q 2013 Earnings Report,2013-11-13 10:48:00-05:00,TROV,neutral
1255376.0,James Altucher Update on Post in Seeking Alpha: 'Trovagene: The 1 Stock That Could've Saved Steve Jobs' Life' ,2013-10-31 10:07:00-04:00,TROV,positive
1255377.0,Trovagene Announces Collaboration for Oncogene Mutation Detection Study ,2013-10-16 05:54:00-04:00,TROV,neutral
1255378.0,Trovagene Abstracts to be Presented at Molecular Targets and Cancer Therapeutics Conference ,2013-10-14 05:54:00-04:00,TROV,negative
1255379.0,Trovagene Awarded NPM Patent,2013-09-25 05:54:00-04:00,TROV,positive
1255380.0,"Market Wrap for Friday, August 30, 2013:  Summer Ending in Turmoil?",2013-08-30 16:31:00-04:00,TROV,negative
1255381.0,"TrovaGene, Inc. Reports Q2 EPS of $(0.30) Which May Not Compare $(0.15) Est",2013-08-14 16:47:00-04:00,TROV,neutral
1255382.0,Trovagene Receives Broad MicroRNA Patent ,2013-07-24 05:48:00-04:00,TROV,neutral
1255383.0,Trovagene Urine-based Cancer Detection Technology Validated ,2013-07-22 05:51:00-04:00,TROV,negative
1255384.0,UPDATE: Cantor Fitzgerald Initiates Trovagene at Buy on Unique Technology Platform,2013-07-16 08:23:00-04:00,TROV,neutral
1255385.0,"Cantor Fitzgerald Initiates Coverage on TrovaGene, Inc. at Buy, Announces $10.00 PT",2013-07-16 07:29:00-04:00,TROV,neutral
1255386.0,"From Earlier: Roth Capital Initiates Coverage on TrovaGene, Inc. at Buy, Announces $11.00 PT",2012-12-20 10:26:00-05:00,TROV,neutral
1255387.0,Aegis Evaluates Chinese Bio Firms,2012-12-12 09:34:00-05:00,TROV,neutral
1255388.0,"UPDATE: Aegis Capital Initiates Coverage on TrovaGene with Buy Rating, $12 PT",2012-12-12 09:02:00-05:00,TROV,neutral
1255389.0,"Aegis Capital Initiates Coverage on TrovaGene, Inc. at Buy, Announces $12.00 PT",2012-12-12 08:23:00-05:00,TROV,neutral
1255390.0,Trovagene Announces Urine-Based Molecular Diagnostic Test for Transrenal Cancer Mutation Monitoring ,2012-11-28 06:21:00-05:00,TROV,negative
1255391.0,Trovagene and Strand Life Sciences Sign Agreement  for Urine-Based HPV Test in India and South Asia ,2012-09-20 06:23:00-04:00,TROV,positive
1255392.0,A Peek Into The Market Before The Trading Starts,2012-08-29 07:18:00-04:00,TROV,neutral
1255393.0,"Trovagene, Inc., Achieves Intellectual Property Milestone under License Agreement with Ipsogen ",2012-08-29 06:11:00-04:00,TROV,positive
1255394.0,TrovaGene Halted on Circuit-Breaker,2012-07-23 09:49:00-04:00,TROV,neutral
1255395.0,"Trovagene, Inc., Announces Issuance of U.S. Patent for NPM Mutants to Diagnose and Monitor Acute Myeloid Leukemia ",2012-07-18 06:46:00-04:00,TROV,neutral
1255396.0,"Trovagene, Inc. Announces Full Exercise of Over-Allotment Option by Aegis Capital Corp. ",2012-06-13 13:50:00-04:00,TROV,neutral
